How do you choose between olaparib vs talozaparib for patients with germline BRCA mutated metastatic breast cancer who are eligible for a PARP inhibitor?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Metastatic

Is there any data about one being better than the other based on patient/disease specific characteristics?

Related Questions

Do you have a preference of denosumab over zoledronic acid in patients with metastatic breast cancer with osseous involvement with normal renal function?

Is there a role for Elacestrant in ER+ metastatic breast cancer with ESR1-YAP1 fusion on NGS?

Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?

How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?

Since the publication of DESTINY-Breast-04 have you implemented new institutional practices for characterization of HER2-low disease given known limitations in pathologist IHC evaluation?

Would you use elacestrant in a patient with an ESR1-AKAP12 fusion?

How do you treat metastatic breast cancer which is HR positive, Her2 negative with PIK3CA+ and high tumor mutational burden (>10) who progressed after prior ET+CDK 4/6 and PIK3CA inhibitor therapy?

In a patient with metastatic HR+/HER2- breast cancer who progressed on adjuvant hormonal therapy, do you start fulvestrant + CDK4/6i or do you wait for NGS testing to determine eligibility for targeted agents such as elacestrant or PIK3CA inhibitors?

How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?

Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?